Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week randomized double-blind study of EMP16-120/40 with acarbose versus orlistat formulations in overweight or obese participants
2022-003320-40Phase 2Completed
- Sponsor
- Empros Pharma
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of EMP16 in obesity and Overweight (3 arms), sponsored by Empros Pharma. Primary endpoint: Co-primary endpoints. Started Jan 2023; status: completed.
02
Drugs
EMP16
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2022-003320-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003320-40.